Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

被引:7
|
作者
Li, Zheng [1 ,2 ]
Wang, Jun [1 ,2 ]
Ge, Shuai-Shuai [1 ,2 ]
Qiu, Qiao-Cheng [1 ,2 ]
Du, Jia-Hui [3 ]
Shan, Shuang-Shuang [3 ]
Shen, Xiang-Dong [1 ,2 ]
Wan, Chao-Ling [1 ,2 ]
Wang, Bin-Ru [1 ,2 ]
Wu, De-Pei [1 ,2 ]
Qiu, Hui-Ying [1 ,2 ]
Xue, Sheng-Li [1 ,2 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Soochow Univ, Collaborat Innovat Ctr Hematol, Inst Blood & Marrow Transplantat, Suzhou, Peoples R China
[3] Suzhou Vocat Hlth Coll, Suzhou Key Lab Med Biotechnol, Suzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
中国国家自然科学基金;
关键词
venetoclax; azacitidine; midostaurin; t(8; 21); relapsed acute myeloid leukemia; KIT mutation; targeted therapy; MUTATIONS; CANCER; ADULTS;
D O I
10.3389/fonc.2022.841276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia (AML) with t(8;21) is categorized as favorable-risk AML, but KIT mutations show a significantly poor prognostic impact in such patients. Persistent vulnerability to relapse is a major challenge in the treatment of this subtype of patients. Venetoclax is a BCL-2 selective inhibitor. The venetoclax+HMA strategy is also a notable salvage regimen that achieves good clinical outcomes in the treatment of relapsed or refractory (R/R) AML. However, in our clinical practice, we found that disease progressed rapidly even after venetoclax+azacitidine (AZA) therapy in two relapsed t(8;21) AML patients with KIT mutations. We report for the first time the therapeutic potential of venetoclax+midostaurin as a new combination therapy for relapsed t(8;21) AMLs with KIT mutations showing resistance to venetoclax+AZA therapy. Our ex vivo study also showed that midostaurin alone could inhibit proliferation and induce apoptosis of Kasumi-1 cells (e.g. Midostaurin induced G2 phase cell arrest, down-regulated p-KIT and BCL-2, while Bax protein levels were up-regulated) and observed a synergistic anti effect when the two drugs were combined. Our study shows that the venetoclax+midostaurin regimen may be a promising treatment option for R/R t(8;21) AML with KIT mutations.
引用
收藏
页数:6
相关论文
共 31 条
  • [1] Venetoclax in combination with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia
    Che, Yue
    Tan, Wanqing
    Liu, Ying
    Liu, Haitao
    Li, Lanlan
    Qin, Fangmei
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01) : 209 - 214
  • [2] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    CANCERS, 2022, 14 (08)
  • [3] Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
    Fleischmann, Maximilian
    Jentzsch, Madlen
    Brioli, Annamaria
    Eisele, Florian
    Frietsch, Jochen J.
    Eigendorff, Farina
    Tober, Romy
    Schrenk, Karin G.
    Hammersen, Jakob Friedrich
    Yomade, Olaposi
    Hilgendorf, Inken
    Hochhaus, Andreas
    Scholl, Sebastian
    Schnetzke, Ulf
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 285 - 294
  • [4] Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia
    Murakami, Hiroyuki
    Matsuoka, Ken-ichi
    Asano, Takeru
    Moriyama, Takashi
    Matsumura, Akifumi
    Fujiwara, Hideaki
    Asada, Noboru
    Ennishi, Daisuke
    Nishimori, Hisakazu
    Fujii, Keiko
    Fujii, Nobuharu
    Toji, Tomohiro
    Yoshino, Tadashi
    Maeda, Yoshinobu
    CASE REPORTS IN ONCOLOGY, 2022, 15 (03): : 974 - 979
  • [5] Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients
    Petit, C.
    Saillard, C.
    Mohty, B.
    Hicheri, Y.
    Villetard, F.
    Maisano, V.
    Charbonnier, A.
    Rey, J.
    D'Incan, E.
    Rouzaud, C.
    Gelsi-Boyer, V.
    Murati, A.
    Lhoumeau, A. C.
    Ittel, A.
    Mozziconacci, M. J.
    Alary, A. S.
    Hospital, M. -A.
    Vey, N.
    Garciaz, S.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (04) : 530 - 537
  • [6] Hemophagocytic Lymphohistiocytosis Secondary to Refractory Acute Myeloid Leukemia Resolved after Second-Line Treatment with Azacitidine plus Venetoclax
    Zorzetto, Francesco
    Scalas, Alessandra
    Longu, Francesco
    Isoni, Maria Antonia
    Angelucci, Emanuele
    Fozza, Claudio
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 16 (01)
  • [7] Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis
    Guinan, Kimberly
    Mathurin, Karine
    Au, Yunghan
    Schuh, Andre C.
    Bui, Cat N.
    Chai, Xinglei
    Lachaine, Jean
    CURRENT ONCOLOGY, 2022, 29 (10) : 7524 - 7536
  • [8] Venetoclax and Azacitidine Treatment in Relapsed Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation: A Cohort Study in the Real-World Setting of a Tertiary Center
    Goker, Hakan
    Cinar, Olgu Erkin
    Demiroglu, Haluk
    Malkan, Uemit Yavuz
    Karakulak, Elifcan Aladag
    Buyukasik, Yahya
    TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 (03) : 213 - 215
  • [9] Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia
    Yu, Guopan
    Yin, Zhao
    Jin, Hua
    Yu, Sijian
    Li, Yuhua
    Nie, Danian
    Guo, Ziwen
    Sun, Zhiqiang
    Meng, Qingxiang
    Zhao, Weihua
    Lin, Dongjun
    Xu, Na
    Zhang, Yu
    BLOOD, 2022, 140 : 11796 - 11796
  • [10] Acute Myeloid Leukemia Harboring the t(16;21) (p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation
    Teshima, Kazuaki
    Ikeda, Sho
    Abe, Ko
    Yamada, Masahiro
    Takahashi, Naoto
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)